Sol-Gel Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Sol-Gel reported Q1 2026 revenue of $0.1 million and a net loss of $3.7 million, driven by a significant reduction in R&D expenses compared to the prior year. The company closed an oversubscribed $33.1 million underwritten offering, bringing total liquidity to $52.8 million and extending its cash runway into the first quarter of 2028.
Key figures
- Revenue
- 108000
- Drug Name
- SGT-610 (patidegib gel, 2%)
- Revenue Yoy
- -89%
- Deal Value Usd
- 33100000
- Phase Of Trial
- Phase 3
- Net loss
- 3727000
- Rd expense
- 2786000
- Cash runway
- Q1 2028
- Patent expiry
- 2044
- G and a expense
- 1177000
- Cash and equivalents
- 10136000
- Marketable securities
- 42692000
- Upfront milestone potential
- 4500000
- Potential annual royalties 2031
- 10000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.